By Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant. Biosimilars, less expensive treatments made to closely emulate biologics with expired patents,… The post What sets oncology biosimilars apart: Anticipating key challenges in the dev...
